U.S. mid-cap stocks have attracted significant interest as companies across various sectors capitalize on emerging growth opportunities. Likewise, the stocks have remained resilient in a choppy market amid heightened volatility triggered by monetary policy uncertainty, geopolitical tensions, and economic growth concerns. The S&P Midcap 400 is up by about 10%.
While large-cap stocks continue to dominate market discussions, mid-cap companies offer investors exposure to businesses with significant expansion potential, established operations, and opportunities to gain market share.
Some mid-cap stocks have delivered exceptional returns. Strong earnings, improving business fundamentals, strategic partnerships, and favorable industry trends have helped drive gains in the individual companies, allowing some to outperform the broader market. However, the stocks have entered a more selective phase, like small-cap stocks after a strong first half of the year.
Rising bond yields threaten to put pressure on the equity market. However, analysts at Jefferies, in a post on CNBC, insist small value stocks are poised to weather the storm better than large companies.
Photo by AlphaTradeZone on Pexels
“Over a longer period, higher [rates] for longer has been good for small, value, and cyclicals,” small and mid-cap strategist Steven DeSanctis said
Meanwhile, the outlook for U.S. mid-cap stocks is optimistic, with the potential for further gains if economic growth remains resilient and interest rates become more favorable. The stocks could offer investors an attractive balance between the growth potential of small-cap stocks and the relative stability of large-cap companies.
Additionally, mid-cap stocks could continue to attract interest from investors seeking exposure outside large technology companies whose valuations appear to have gotten out of hand. If large-cap stocks become expensive relative to their earnings prospects, investors may look toward smaller businesses with stronger growth potential or more reasonable valuations. Take a look at the stocks Michael Burry is watching amid AI and tech stock concerns.
In this article, we examine the best-performing U.S. mid-cap stocks in 2026, highlighting the companies that have delivered the strongest returns and the key factors behind their performance.
Our Methodology
To create the list of the 10 Best Mid-Cap U.S. Stocks to Buy Now, we used screeners to identify mid-cap stocks with a market cap between $2 billion and $10 billion that have a consensus ‘Strong Buy’ rating among analysts. Next, we focused on US stocks that have gained more than 20% year-to-date and are popular among elite hedge funds in Q2 2026. The list is presented in ascending order of the number of hedge funds that hold stakes in the stocks.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Best mid-cap US stocks to buy now
10. Krystal Biotech Inc. (NASDAQ:KRYS)
Number of Hedge Fund Holders: 29
Market Cap as of October 30: $9.61 Billion
Year-to-Date Gain as of October 30: 31.44%
Krystal Biotech, Inc. (NASDAQ:KRYS) stands out among the best mid-cap US stocks to buy now, supported by the commercial success of its gene therapy portfolio. Strong sales growth from its flagship treatment, Vyjuvek, and opportunities to expand into additional rare-disease markets have strengthened investor sentiment. The stock has gained approximately 31% in 2026, outperforming the broader mid-cap market. Is the stock still a Buy?
The rally reflects Vyjuvek’s growing commercial success, as it establishes Krystal Biotech, Inc. as a revenue-generating company in the specialized gene therapy market. In the second quarter of 2026, net sales of the treatment increased 24% to $119.2 million, while its gross margin reached 95%.
Cumulative sales since launch have climbed to $965.9 million, demonstrating the company’s ability to commercialize its treatment and generate substantial revenue. Explore the company’s resilient revenue stream.
Beyond Vyjuvek, Krystal Biotech, Inc. has a pipeline of experimental therapies that could provide additional growth opportunities. It includes KB407 for cystic fibrosis and KB803 for corneal complications associated with dystrophic epidermolysis bullosa. As a result, the company has solid growth avenues.
Wall Street analysts have also expressed optimism about the company’s prospects. On October 15, Citi raised its price target of the stock to $416 from $386 and reiterated a Buy rating. The price target increase follows a clinical update on KB113 for treating basal cell carcinomas in patients with Gorlin syndrome. Earlier on September 24, Goldman Sachs resumed coverage of Krystal Biotech, Inc. with a Buy rating.
9. Navan, Inc. (NASDAQ:NAVN)
Number of Hedge Fund Holders: 38
Market Cap as of October 30: $6.93 Billion
Year-to-Date Gain as of October 30: 63.88%
Navan, Inc. (NASDAQ:NAVN) is one of the best mid-cap US stocks to buy now, owing to rising demand for its AI-powered corporate travel and expense management platform. The company has carved a niche in helping businesses manage corporate travel bookings, payments, and expense reporting through an integrated platform.
Rising demand for its solutions fueled strong second-quarter fiscal 2027 results, with revenue increasing 35% year over year to $232.8 million. Gross booking volume also climbed 45% to $3 billion, reflecting growing customer adoption and higher platform usage.
Moreover, Navan, Inc. raised its full-year revenue guidance to a range of $927 million to $933 million, signaling management’s confidence in sustaining its growth momentum. Explore why management hiked guidance.
Artificial intelligence is also emerging as an important growth driver for the company. Navan’s AI-powered travel assistant and automated customer support tools are enhancing the travel experience by helping users manage bookings while allowing businesses to streamline expense management.
The company has also deployed NVIDIA Nemotron 3.5 Super VL to power several of its AI travel agents, further strengthening its automation capabilities. Why did Navan collaborate with Engine?
Strong revenue growth, expanding enterprise adoption, AI-driven automation, and progress toward improved adjusted profitability reinforce Navan, Inc.’s position as a compelling mid-cap stock.
8. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Number of Hedge Fund Holders: 43
Market Cap as of October 30: $9.34 Billion
Year-to-Date Gain as of October 30: 65.57%
A 300%+ rally underscores why Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the best mid-cap US stocks to buy now. The explosive rally comes from the company establishing itself in the development of peptide-based therapies to treat inflammatory bowel disease.
Investor sentiment has strengthened as Protagonist Therapeutics moves beyond its clinical-stage biotechnology roots. It has already secured two FDA-approved medicines through partnerships with major pharmaceutical companies. Read how two drugs are nearing blockbuster status.
ICOTYDE (icotrokinra) is one of its lead products developed in collaboration with Johnson & Johnson, for moderate-to-severe plaque psoriasis. The FDA has also approved MIMRYLO (rusfertide) to treat erythrocytosis in adults with polycythemia vera, a rare blood cancer. The approval triggered a $275 million milestone payment, with the company also eligible for up to $875 million in additional milestones.
Protagonist Therapeutics, Inc. is also advancing additional peptide-based therapies, including PN-881, an oral IL-17 antagonist targeting inflammatory diseases. These programs offer additional growth opportunities and could further expand the company’s therapeutic reach.
Protagonist Therapeutics, Inc. is an attractive mid-cap biotechnology growth story because it combines two FDA-approved medicines, partnerships with major pharmaceutical companies, substantial financial resources, and an expanding drug-development pipeline.
7. Element Solutions Inc (NYSE:ESI)
Number of Hedge Fund Holders: 44
Market Cap as of October 30: $8.59 Billion
Year-to-Date Gain as of October 30: 36.47%
Element Solutions Inc (NYSE:ESI) is one of the best mid-cap US stocks to buy now, thanks to the competitive advantage of its Electronics business, which supplies specialty chemicals and materials used in semiconductor packaging.
The company is increasingly benefiting as investments in AI data centers accelerate, driving demand for advanced semiconductor packaging and high-performance electronic components. This growing demand for specialized materials is also drawing attention to opportunities across the nuclear and energy sectors. For more insights, see Jim Cramer Might Have Revealed A Major Hidden Nuclear Stock As Part Of His Discussion Of Materials & Chemical Companies.
Element Solutions delivered robust third-quarter results, with net sales jumping 52% to $995 million, up 13% organically. Net income increased to $66 million from $39 million a year ago. Adjusted EBITDA increased to $191 million. Management reiterated that it expects the growth momentum to continue into year-end, raising its full-year 2026 adjusted EBITDA forecast to approximately $720 million, up from its previous guidance of $650 million to $670 million.
On October 22, Mizuho raised its price target to $44 from $42 while reiterating a neutral rating after the impressive results. Earlier, on October 12, Barclays initiated coverage with a $53 price target and an overweight rating. What happened to the proposed Solstice merger?
Element Solutions stands out among mid-cap stocks because of its exposure to the expanding AI and semiconductor markets. Strong third-quarter performance, accelerating growth in its Electronics business, and an upward revision to its full-year earnings outlook reinforce its growth prospects.
6. Kirby Corporation (NYSE:KEX)
Number of Hedge Fund Holders: 44
Market Cap as of October 30: $7.71 Billion
Year-to-Date Gain: 30.47%
Kirby Corporation (NYSE:KEX) is one of the best mid-cap US stocks to buy now, combining improving marine transportation fundamentals with growing demand for power generation equipment and services. The stock has gained more than 30% year-to-date, outperforming the broader market.
The outperformance comes against the backdrop of the company’s strong position in transporting bulk liquid commodities across U.S. waterways. Likewise, Wall Street is already taking note, with JPMorgan initiating coverage on October 14 with an Overweight rating and a $200 price target. The investment sees the stock as a high risk-reward play, given tight supply and demand behind data center-driven power demand. Explore how Kirby is gaining from the distribution and services segment.
Meanwhile, Stephens raised its price target to $175 from $170 and reiterated an Overweight rating on October 29, impressed by adjusted earnings estimates. The company says it expects its full-year earnings per share to come in at the upper end of the 10% to 15% range. The upgrade comes on third-quarter earnings increasing by 27% to $2.09a share as marine transportation revenues increased 17%.
Kirby Corporation’s operating performance and exposure to data center infrastructure make it an interesting mid-cap stock to research.
5. Brinker International, Inc. (NYSE:EAT)
Number of Hedge Fund Holders: 48
Market Cap as of October 30: $9.21 Billion
Year-to-Date Gain as of October 30: 45.13%
Strong restaurant sales growth and improving profitability underscore why Brinker International, Inc. (NYSE:EAT) is one of the best mid-cap US stocks to buy now. The company has capitalized on renewed consumer demand for its Chili’s Grill & Bar brand, supported by menu innovation and competitive pricing. Is Brinker the turnaround restaurant story of the year?
Its ability to attract more customers and drive higher restaurant traffic has translated into solid financial performance. In the first quarter of fiscal 2027, revenue increased 9.4% year over year to $1.48 billion, while adjusted earnings of $2.77 per share exceeded analyst expectations.
A key contributor to this growth has been Chili’s successful turnaround. The brand recorded its 22nd consecutive quarter of comparable sales growth, with same-store sales increasing 10% in the latest quarter.
Wall Street analysts are already taking note of the impressive underlying growth. Seaport Research raised the stock price target to $250 on October 30, buoyed by the strong financial results. DA Davidson also reiterated its neutral rating but raised the price target to $220 from $210 following the first-quarter results. Is it a good stock to buy?
Brinker International, Inc.’s performance highlights how a successful brand turnaround, stronger restaurant traffic, and disciplined execution can support sustained comparable sales growth, improve profitability, and drive higher earnings.
4. Hinge Health, Inc. (NYSE:HNGE)
Number of Hedge Fund Holders: 48
Market Cap as of October 30: $9.43 Billion
Year-to-Date Gain as of October 30: 156.58%
Hinge Health, Inc. (NYSE:HNGE) is one of the best mid-cap US stocks to buy now, operating at the intersection of digital healthcare, artificial intelligence, and employer-sponsored healthcare benefits. The stock has surged more than 150% year-to-date, reflecting growing investor confidence in its business prospects. Despite the significant rally, Wall Street analysts remain bullish on its long-term growth potential.
On October 26, Stifel reiterated a Buy rating and raised its price target to $130 from $115. The hike came on the company delivering the strongest downloads on its Hinge Health App. Earlier on October 23, BofA also raised its price target to $130 from $110 and kept a buy rating, as KeyBanc raised its price target by $15 to $140. Explore what’s fuelling Hinge Financials.
The positive analyst sentiment comes amid growing adoption of Hinge Health’s digital healthcare solutions. Strong adoption is supported by strong financial performance: revenue rose 53% in the second quarter, and operating income increased 136%. The company also raised its full-year 2026 revenue guidance to 860 million, representing approximately 46% growth. Could Hinge win on digital healthcare expansion?
Another reason Hinge Health stands out is its ability to expand beyond traditional musculoskeletal care. It has already introduced specialized programs covering women’s pelvic health, fall prevention, and migraine care. It has also inked relationships with large employers, health plans, and pharmacy benefit managers.
3. Vicor Corporation (NASDAQ: VICR)
Number of Hedge Fund Holders: 55
Market Cap as of October 30: $9.54 Billion
Year-to-Date Gain as of October 30: 76.81%
Vicor Corporation (NASDAQ:VICR) stands out as one of the best mid-cap US stocks to buy now because of its exposure to high-performance power management, artificial intelligence, and advanced computing systems. The stock has gained more than 70% year-to-date, significantly outperforming the Insider Monkey Billionaire Index, which is up approximately 29% over the same period.
The strong performance reflects growing demand for the company’s power delivery technology as data centers, AI accelerators, and high-performance computing systems require increasingly sophisticated power architectures. Likewise, the company is capitalizing on rising demand for AI-related power solutions. Can the company scale?
Momentum was evident in the third quarter of fiscal 2026, when revenue rose 78.5% to $197.1 million. Net income also more than doubled to $63.3 million. Cash flow from operations also more than doubled to $69.7 million. Backlog rose 7% quarter-over-quarter to $406 million in the third quarter of 2026, up 166% from $153 million a year earlier.
Additionally, Vicor Corporation is benefiting from an expanding licensing business. It has secured its first VPD (vertical power delivery) license with an AI original equipment manufacturer (OEM), which is set to generate royalties. Read how Vicor is licensing its power patents.
Overall, Vicor Corporation offers exposure to the expanding AI infrastructure market through its specialized power management technology. Accelerating revenue growth, improving profitability, a growing backlog, and new licensing opportunities position the company to benefit from rising demand for advanced power solutions.
2. Darling Ingredients Inc. (NYSE:DAR)
Number of Hedge Fund Holders: 63
Market Cap as of October 30: $8.70 Billion
Year-to-Date Gain as of October 30: 71.65%
Darling Ingredients Inc. (NYSE:DAR) is one of the best mid-cap US stocks to buy now, supported by its exposure to renewable fuels, waste recycling, and sustainable agricultural products. A major catalyst behind the stock’s outperformance versus the overall market, with a 71% year-to-date gain, is its renewable fuels business.
Darling Ingredients Inc. owns a 50% stake in Diamond Green Diesel (DGD) that produces renewable diesel and sustainable aviation fuel. The business is benefiting from government policies pushing lower-carbon fuels and rising demand for alternatives to conventional petroleum-based diesel.
Additionally, it is benefiting from growing demand for specialty food and health ingredients through its Rousselot and Gelnex businesses that produce collagen and gelatin used in pharmaceuticals and nutritional supplements.
In the third quarter, revenue rose 14.5% to $1.79 billion, while net income increased to $267 million, or $1.67 a share, compared to $19.4 million, or $0.12 a share, in the third quarter last year. The company also strengthened its balance sheet by reducing net debt by about $420 million during the third quarter. Explore potential margin expansion.
Darling Ingredients Inc. offers exposure to several long-term growth themes, including renewable energy and specialty nutrition. Its improving operating performance, diversified business model, and debt-reduction efforts are key elements of its investment case.
1. Viavi Solutions Inc. (NASDAQ:VIAV)
Number of Hedge Fund Holders: 72
Market Cap as of October 30: $8.19 Billion
Year-to-Date Gain as of October 30: 83.58%
Viavi Solutions Inc. (NASDAQ:VIAV) is one of the best mid-cap US stocks to buy now, supported by its exposure to expanding technology markets, including 5G, fiber-optic networks, and artificial intelligence (AI). The company is benefiting from accelerating AI investments, which are driving demand for high-speed optical connectivity and advanced network infrastructure.
This growing demand has translated into strong financial performance. It delivered strong fiscal fourth-quarter 2027 results, with revenues up 52.5% to $443.1 million as earnings per share climbed 161.5% to $0.34. Full-year revenue was up 40% to $1.52 billion, and EPS more than doubled to $1. Is Viavi a good stock to buy?.
The acquisition of Spirent Communications’ high-speed Ethernet, network security, and channel emulation testing businesses has strengthened Viavi Solutions Inc.’s growth prospects. The business is positioned to benefit from increasing demand for high-speed connectivity as hyperscalers and technology companies expand AI computing infrastructure.
Viavi Solutions Inc. is also benefiting from growing demand for aerospace and defense technologies as its positioning, navigation, and timing (PNT) solutions support military communications. This offers additional growth opportunities as governments increase spending on defense modernization.
READ NEXT: 10 Best Low Priced Technology Stocks to Invest In and 12 Best Stocks to Buy for the AI Boom in the Second Half of 2026
